BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
V. The repeatedly talk about "heart failure" as a measurable end point but little else about it As it stands this is a meaningless termis it re-admission for heart failure (i.e bed days) +/-drug costs they are referring to ? VI. Are they accounting anywhere for expensive beds (i.e. CCU/ITU) or do they expect all the CGS patients to be managed in identical Units -I think the practice will vary and the cost of the bed should be included. VII. They include ICD costs (correctly) but little other MSD and nothing on resynchronisation therapy. VIII. It is unclear how the C/E data will be managed in terms of differences in any early mortality between groups. IX. Neither of these treatments is standard therapy since it is unclear what should be done although the Guidelines recommend complete revascularisation. Are they trying to prove that the Guidelines should be followed even if it could be more expensive? What is the rationale? Scatter plot quadrant boxes are often used to indicate where the cost efficacy lies -is that the plan here and if so what is the underlying ethos they are aiming at i.e which box? This paper sets out an important aspect that should be mandate for any trial of this nature. The choice of renal failure rather than or in addition to re-admission for heart failure is an odd component of the primary end point but that is not the fault of the health economist authors.
REVIEWER

Dr Nicholas D Gollop
The University of East Anglia Norwich Research Park Norwich NR4 7UQ REVIEW RETURNED 05-Dec-2016
GENERAL COMMENTS
Thank you for inviting me to review this manuscript, entitled: "Protocol for economic evaluation of the randomised controlled trial of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial".
I would like to congratulate the authors on an impressive protocol which aims to compare the cost-effectiveness of immediate multivessel revascularisation vs culprit vessel only PCI +/-staged subsequent revascularisation; data acquired from the recently published CULPRIT-SHOCK trial.
The protocol is well developed and is logical. As a clinician, the idea and the methods suggested all appeared appropriate, however my sense was that the complexity of aspects (such as bootstrapping, and net-monetary benefit, for example) were rather complex and not clearly explained. I would suggest that the readership of BMJ Open would benefit from having the complexities of the protocol simplified to enable clear understanding and synthesis of the proposed work.
A second comment is that the protocol does not appear to have been 'tested' against an additional data set. This would seem to be an important process as a testing phase would highlight protocol weaknesses/problems, which if undetected, could render the study invalid/interpretable. Therefore I suggest the following:
1) I think this study does need to be reviewed by a statistician for methodological rigor 2) The authors need to review the content and adjust the 'level' to suit the target audience 3) Back-testing of this protocol on pre-existing data would add significant value to the study -and furthermore highlight any future, potentially preventable problems.
I would be happy to re-review with these consideration accounted for. Thank you and best wishes. R1. The authors have set out to deliver the overview of the cost efficacy analysis for the "CULPRIT-SHOCK Trial". This is an on-going study that definitively needs a cost efficacy sub-study since although the randomised arms are not standard treatment versus "expensive" kit the randomised treatments may as a strategy lead to the need for different forms of mechanical support. However none of this important background is really explored by the authors. AUTHOR REPLY:
VERSION 1 -AUTHOR RESPONSE
We absolutely agree with the reviewer's comment. The need for the economic evaluation for this trial relies on the fact that while we could expect culprit vessel revascularization to be a safer strategy for patients with cardiogenic shock, there are reasons to believe that it could entail higher costs due to subsequent planned revascularization and different used resources. Furthermore, other additional treatments such as higher or lower use of mechanical support devices in the two trial arms may influence costs. Therefore, the need and the differential use for mechanical support devices are recorded in the eCRF for further cost evaluation.
CHANGES IN THE PAPER:
We have changed the last paragraph of the BACKGROUND section for the next paragraph: "This study protocol addresses the third decision problem. The need for a cost-effectiveness analysis relies on the fact that we could expect culprit vessel revascularization to be a safer strategy for patients with cardiogenic shock and, at the same time, there are reasons to anticipate higher costs due to the need for subsequent staged revascularization and different resources like mechanical support devices". R1. The paper is well written by experts in health economics albeit rather overlong. They need to stick to this trial rather than provide CEA background for example para 3. We agree with the reviewer in that the trial is only powered for clinical outcomes (i.e. survival rate and renal failure) but not for health economic outcomes (e.g. QALYs) and costs. The difference between the clinical perspective and the perspective of economic evaluation is that, while the former is aimed at statistical hypothesis testing, the latter is aimed at estimating differential costs, health outcomes and cost-effectiveness ratios. The estimation of uncertainties around cost-effectiveness of the two alternative treatments is one part of the economic evaluation itself. In this sense the trial will provide the information required to build confidence intervals and sensitivity analyses for the costeffectiveness. R1. II It is unclear when the cost efficacy analysis is being done Para 2.2 and 2.3 are unclear. Why are they collecting data at the various time points (Table 1 ) Do they expect there to be sufficient difference at 30 days -surely it would be more sensible to undertake a CEA evaluation just at 12 months AUTHOR REPLY: We agree that sections 2.2 and 2.3 were unclear about the timing of the cost efficacy analysis. Three different economic analyses will be done depending on the type of analysis and the period covered. On the one hand, the CEA analysis will be done using information for the first 30 days after randomization. On the other hand, two different periods for the CUA will be considered. First, a within trial analysis will include information collected during the 1-year follow-up period. Second, a long term model based CUA will be performed to account for lifetime health outcomes and costs. We expect the 30-day period to be enough for detecting differences in mortality rate and renal failure given that the sample has been powered for those two outcomes. In addition, we expect this period to be accounting for major differences between the two treatments since the literature shows that a huge majority of the mortality events occur within the first 30 days after revascularization (see Figure 2 We have changed the paragraph 2.4 for more clarity on the fact that we are performing an economic evaluation taking costs and outcomes relevant to the health care systems (i.e. a health system perspective) and we include loss of productivity incurred by the patients (i.e. a societal perspective).
We have changed section 2.4 for more clarity. R1. IV. I tis unclear how they are going to adjust for differences in cost between different national health systems-will they ask for representative costs from each National centre or are they going to somehow adjust the German costs? AUTHOR REPLY: The analysis will comprise two different ways to deal with this multinational trial. On the one hand, a multi-country analysis will apply country specific unit costs to each resource used and derive a cost effectiveness global result. On the other hand, single country analysis will be considered by applying one country unit costs to the whole resources used to derive a cost effectiveness result for specific countries.
We have changed last paragraph of section 2.7 for more clarity. R1. V. The repeatedly talk about "heart failure" as a measurable end point but little else about it As it stands this is a meaningless term -is it re-admission for heart failure (i.e bed days) +/-drug costs they are referring to ? AUTHOR REPLY: We acknowledge that the term "heart failure" may refer to several meanings. In the context of our study this could mean: 1) need for re-admission due to heart failure, or; 2) a chronic health condition in which a patient remains his/her entire life. Both of these events are included in the eCRF.
Specifically, in our model we are using the second concept in such a way that we expect that a patient with heart failure has lower quality of life and need for long term treatment. In the same way renal failure is expected to be a long term condition needing renal replacement therapy. CHANGES IN THE PAPER:
We have added an explanatory note to Table 1 for heart and renal failure. R1. VI. Are they accounting anywhere for expensive beds (i.e. CCU/ITU) or do they expect all the CGS patients to be managed in identical Units -I think the practice will vary and the cost of the bed should be included. , LVADs, heart transplantation), treatments of renal failure, heart failure, and MACE will constitute the cost of health services use (CHServ)." R1. VIII. It is unclear how the C/E data will be managed in terms of differences in any early mortality between groups. AUTHOR REPLY: All early mortality and associated costs will be collected by the 30-day follow up. Therefore they will be included in the analysis. R1. IX. Neither of these treatments is standard therapy since it is unclear what should be done although the Guidelines recommend complete revascularisation. Are they trying to prove that the Guidelines should be followed even if it could be more expensive? What is the rationale? Scatter plot quadrant boxes are often used to indicate where the cost efficacy lies -is that the plan here and if so what is the underlying ethos they are aiming at i.e which box? AUTHOR REPLY: The analysis will explore to what extent culprit vessel only revascularization is a more/less cost effective strategy than complete revascularization. Following our beliefs/expectation about culprit vessel only revascularization being more costly and more effective we define the ICER as: ICER=(Cost_co -Cost_mv)/(QALY_co -QALY_mv ). In this sense, we expect the scatterplot of the cost effectiveness plane to be placed in the right top quadrant mainly. R1. This paper sets out an important aspect that should be mandate for any trial of this nature. The choice of renal failure rather than or in addition to re-admission for heart failure is an odd component of the primary end point but that is not the fault of the health economist authors. AUTHOR REPLY: Renal failure is a likely health condition for patients having AMI complicated with cardiogenic shock. Due to its relevance in this specific case and the high costs for the associated treatment we included it in the economic evaluation. R2. Thank you for inviting me to review this manuscript, entitled: "Protocol for economic evaluation of the randomised controlled trial of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial". I would like to congratulate the authors on an impressive protocol which aims to compare the costeffectiveness of immediate multi-vessel revascularisation vs culprit vessel only PCI +/-staged subsequent revascularisation; data acquired from the recently published CULPRIT-SHOCK trial. The protocol is well developed and is logical. As a clinician, the idea and the methods suggested all appeared appropriate, however my sense was that the complexity of aspects (such as bootstrapping, and net-monetary benefit, for example) were rather complex and not clearly explained. I would suggest that the readership of BMJ Open would benefit from having the complexities of the protocol simplified to enable clear understanding and synthesis of the proposed work. A second comment is that the protocol does not appear to have been 'tested' against an additional data set. This would seem to be an important process as a testing phase would highlight protocol weaknesses/problems, which if undetected, could render the study invalid/interpretable. Therefore I suggest the following: I think this study does need to be reviewed by a statistician for methodological rigor AUTHOR REPLY AND CHANGES:
We have made an effort to improve the readability of the paper by making it shorter and clearer. For example, we have improved the explanation about the resources use and the multi-country costing methodology in section 2.7. See also changes to text for grammatical improvements in sections 2.2, 2.3, 2.8, 3.1, 3.2 and 3.3. R2.
2) The authors need to review the content and adjust the 'level' to suit the target audience AUTHOR REPLY AND CHANGES:
We have tried to make the text friendlier for a non-specialist audience. For example, we have included in section 3.1 a more concise explanation for NMB indicating the interpretation of the lambda parameter in the equation, i.e. lambda is interpreted as the monetary value of a QALY. In addition, we have eliminated excess detail in the explanation of the bootstrapping exercise for uncertainty estimation in section 3.3., now we only refer to "non-parametric bootstrapping techniques" without mentioning any specific number of replications. R2. 3) Back-testing of this protocol on pre-existing data would add significant value to the study -and furthermore highlight any future, potentially preventable problems.
AUTHOR REPLY:
We have previously used the pre-trial model populated with parameters estimated in the relevant clinical and economic literature. The result of this exercise has been the representation of Cost Effectiveness Planes and estimation of ICERs. Some intuitive results were obtained: QALY gains and cost are positively related. Cost effectiveness of culprit vessel only PCI increases as it reduces mortality as well as it improves renal failure. A high probability for staged revascularization in culprit vessel PCI reduces its cost effectiveness.
R2. I would be happy to re-review with these consideration accounted for. Thank you and best wishes VERSION 2 -REVIEW REVIEWER Anthony Gershlick University Hospitals of Leicester REVIEW RETURNED 21-Feb-2017
GENERAL COMMENTS
The authors have addressed most the points as best they can... I think there will be some questions about the primary end point having renal rather than admission for heart failure in it but this is not the problem with this paper Some minor points 1 they dont seem to be measuring the non invasive testing (which is part of Group 2 strategy) as a cost 2. They need to indicate what cost/ QALY they think is reasonable in this trial (NICE £20 000 or NICE £5000 for example 3 Their limitations section is too limited: What are the risks to the project ?/ For example I can think that data collection will be a problem how will that and at what level (50% completeness, 70% complete? 90% complete) will the results become less valid? 4 What are the study team doing about ensuring robust and complete data collection?
VERSION 2 -AUTHOR RESPONSE
Reply to Reviewer: 1 (R1) Reviewer: 1 Reviewer Name: Anthony Gershlick Institution and Country: University Hospitals of Leicester, UK Competing Interests: None Dear Professor Gershlick, Thank you for your comments and suggestions to further improve our manuscript. We offer the following responses.
R1. 1. they don't seem to be measuring the non invasive testing (which is part of Group 2 strategy) as a cost AUTHOR REPLY: Non-invasive testing is included in health services use (CHServ) as investigations costs. We include non-invasive evaluation for residual myocardial ischemia using nuclear perfusion scintigraphy, stress echocardiography, or stress magnetic resonance imaging.
CHANGES IN THE PAPER:
We have included the following explanatory text in section 2.7 for noninvasive testing:
"Intervention costs The resource use for investigations (e.g. non-invasive evaluation for residual myocardial ischemia at 1-4 weeks post index PCI of the culprit lesion such as nuclear perfusion scintigraphy, stress echocardiography, or stress magnetic resonance imaging) and other procedures…" R1. 2. They need to indicate what cost/ QALY they think is reasonable in this trial (NICE £20 000 or NICE £5000 for example) AUTHOR REPLY: A simulation based on a pre-trial model populated with parameters from previous literature on multivessel and culprit lesion only revascularisation of patients with cardiogenic shock gave an average ICER of about 2,000 £/QALY indicating that culprit lesion only PCI would be cost effective at a threshold of £5,000 or £20,000. However, we are cautious in that there is large uncertainty around these estimates since evidence on the two strategies analysed is based on observational data rather on randomised control trials. We acknowledge that parameters based on previous studies could be biased and sensitivity analysis consisting of changing just one parameter (e.g. probability of MACE or renal failure, cost of MACE, ...) could increase the ICER to about £12000.
R1. 3 Their limitations section is too limited:
What are the risks to the project ?/ For example I can think that data collection will be a problem how will that and at what level (50% completeness, 70% complete? 90% complete) will the results become less valid? AUTHOR REPLY: Currently the trial has recruited more than 90% of the sample size of 706 patients. We agree that, as always data completeness will be challenging but the trial is using a well validated eCRF and has a CRO and so far the rates of data completeness are high. Based on the interim analysis there were no relevant problems with respect to missing data.
R1. 4 What are the study team doing about ensuring robust and complete data collection? AUTHOR REPLY: To ensure robust and complete data collection an automated data check for completeness and also data plausibility has been instituted in the electronic Case Report Form (CRF). Furthermore, monitoring ensures data completeness and data plausibility. Furthermore, a final closeout monitoring visit is mandatory for all centres. In addition, case payment is only performed if all data are complete in the electronic CRF and data are checked for plausibility. We have incorporated the next explanation in the first paragraph of the Discussion: "According to a previous analysis performed by us, based on a simulation of this model populated with parameters from the literature, an ICER of about 2,000 £/QALY is expected. However, there is a large uncertainty around these estimates since existing evidence on the two strategies compared is based on observational data rather than on randomised control trials. We acknowledge that parameters could be biased and changing just one parameter (e.g. probability of MACE, or renal failure, or cost of MACE) could increase the ICER to about £12,000."
VERSION 3 -REVIEW
REVIEWER
R1. 3 Their limitations section is too limited: What are the risks to the project ?/ For example I can think that data collection will be a problem how will that and at what level (50% completeness, 70% complete? 90% complete) will the results become less valid? AUTHOR REPLY: We agree that the response was not properly included in the manuscript revision.
CHANGES IN THE PAPER:
We have incorporated the next explanation in the limitations section in the Discussion: "There is a particular challenge with respect to data collection given that the existence of missing information could affect the validity of the results. In that case, statistical techniques will be used to handle missing data. Nonetheless, an automated data check for completeness and data plausibility has been instituted in the eCRF to ensure robust and complete data collection. Furthermore, monitoring ensures data completeness and data plausibility -a final close-out monitoring visit is mandatory for all centres. In addition, case payment is only performed if all data are complete in the eCRF and data are checked for plausibility."
R1. 4 What are the study team doing about ensuring robust and complete data collection? AUTHOR REPLY: See changes in the manuscript above for comment R1. 3.
